Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 2561 · Skin Substitute Access and Payment Reform Act of 2025 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–3a Use of average sales price payment methodology

+41 −14 of 5 shown
More for 42 U.S.C. § 1395w–3a
Read § 1395w–3aOnly this section
5 changes the bill asks for here, 4 carried out
  1. Not carried out:

    subparagraph (B), by striking or at the end;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: subparagraph (X), by striking QTEXT at the end;
  2. Carried out:

    in subparagraph (C), by striking the period at the end and inserting ; or; and

  3. Carried out:

    by adding at the end the following new subparagraph:(D) in the case of a skin substitute product (as defined in subsection (c)(6)(J)), the amount determined under paragraph (9).; and

  4. Carried out:

    by adding at the end the following new paragraph:(9) Skin substitute products.— (A) In general.— Beginning on January 1, 2026, for any skin substitute product (as defined in subsection (c)(6)), the amount specified in this paragraph is the volume-weighted average of the payment allowance limit calculated under subparagraph …

  5. Carried out:

    Section 1847A(c)(6) of the Social Security Act (42 U.S.C. 1395w–3a(c)(6)) is amended by adding at the end the following new subparagraph:(J) Skin substitute products.— (i) In general.— The term “skin substitute product”— (I) means a cellular, biological or synthetic material or tissue applied to a wound and intended to remain within the wound bed, including a product approved, cleared, or authorized to section …

§ 1395w–3a(b)Payment amount(1)–(2)

Start of § 1395w–3a to (b)(1)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(1)(B)(B) (B)
in the case of a single source drug or biological (as defined in subsection (c)(6)(D)), 106 percent of the amount determined under paragraph (4) or in the case of such a drug or biological product that is a selected drug (as referred to in section 1320f–1(c) of this title), with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), 106 percent of the maximum fair price (as defined in section 1320f(c)(3) of this title) applicable for such drug and a year during such period; orin the case of a single source drug or biological (as defined in subsection (c)(6)(D)), 106 percent of the amount determined under paragraph (4) or in the case of such a drug or biological product that is a selected drug (as referred to in section 1320f–1(c) of this title), with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), 106 percent of the maximum fair price (as defined in section 1320f(c)(3) of this title) applicable for such drug and a year during such period; or
(1)(C)(C) (C)
in the case of a biosimilar biological product (as defined in subsection (c)(6)(H)), the amount determined under paragraph (8)[struck: .]in the case of a biosimilar biological product (as defined in subsection (c)(6)(H)), the amount determined under paragraph (8)[inserted: ; or]
(1)(D)(D) [inserted: ]
[inserted: in the case of a skin substitute product (as defined in subsection (c)(6)(J)), the amount determined under paragraph (9).]
(2)(2) Specification of unit(2) Specification of unit
(2)(A)(A) Specification by manufacturer(A) Specification by manufacturer
The manufacturer of a drug or biological shall specify the unit associated with each National Drug Code (including package size) as part of the submission of data under section 1396r–8(b)(3)(A)(iii) of this title or subsection (f)(2), as applicable.The manufacturer of a drug or biological shall specify the unit associated with each National Drug Code (including package size) as part of the submission of data under section 1396r–8(b)(3)(A)(iii) of this title or subsection (f)(2), as applicable.

§ 1395w–3a(b)–(c)

(b)(2)(B)–(8)(B) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(b)(8)(B)(iii)(I)(I) (I)
in the case of a product described in clause (ii)(I), the average sales price under paragraph (8)(A)(i) for a calendar quarter during the 5-year period described in such clause is not more than the average sales price under paragraph (4)(A) for such quarter for the reference biological product; andin the case of a product described in clause (ii)(I), the average sales price under paragraph (8)(A)(i) for a calendar quarter during the 5-year period described in such clause is not more than the average sales price under paragraph (4)(A) for such quarter for the reference biological product; and
(b)(8)(B)(iii)(II)(II) (II)
in the case of a product described in clause (ii)(II), the average sales price under paragraph (8)(A)(i) for a calendar quarter during the 5-year period described in such clause is not more than the average sales price under paragraph (4)(A) for such quarter for the reference biological product.in the case of a product described in clause (ii)(II), the average sales price under paragraph (8)(A)(i) for a calendar quarter during the 5-year period described in such clause is not more than the average sales price under paragraph (4)(A) for such quarter for the reference biological product.
(b)(9)(9) [inserted: Skin substitute products.—]
(b)(9)(A)(A) [inserted: In general.—]
[inserted: Beginning on January 1, 2026, for any skin substitute product (as defined in subsection (c)(6)), the amount specified in this paragraph is the volume-weighted average of the payment allowance limit calculated under subparagraph (B).]
(b)(9)(B)(B) [inserted: Volume-weighted average payment limit.—]
[inserted: The volume-weighted average of the payment allowance limit of a skin substitute product under this paragraph is determined by—]
(b)(9)(B)(i)(i) [inserted: ]
[inserted: calculating the sum of the products of—]
(b)(9)(B)(i)(I)(I) [inserted: ]
[inserted: the published payment allowance limit for each billing and payment code listed in the ASP Pricing File published by the Secretary for the fourth calendar quarter of 2023 for each skin substitute product; and]
(b)(9)(B)(i)(II)(II) [inserted: ]
[inserted: the total number of units, as specified under paragraph (2), for each billing and payment code described in subclause (I), billed with dates of service from October 1, 2023, to December 31, 2023, and listed in the Integrated Data Repository for Part B claims data; and]
(b)(9)(B)(ii)(ii) [inserted: ]
[inserted: dividing the sum calculated under clause (i) by the total number of units under subclause (II).]
(b)(9)(C)(C) [inserted: Updates to payment amounts.—]
[inserted: For 2027 and each subsequent year, the amount specified in this paragraph shall be adjusted for the percentage increase in the consumer price index for all urban consumers (U.S. city average) for the 12-month period ending with June of the previous year.]
(c)(c) Manufacturer’s average sales price(c) Manufacturer’s average sales price
(c)(1)(1) In general(1) In general
For purposes of this section, subject to paragraphs (2) and (3), the manufacturer’s “average sales price” means, of a drug or biological for a National Drug Code for a calendar quarter for a manufacturer for a unit—For purposes of this section, subject to paragraphs (2) and (3), the manufacturer’s “average sales price” means, of a drug or biological for a National Drug Code for a calendar quarter for a manufacturer for a unit—

§ 1395w–3a(c)–(d)

(c)(1)(A)–(6)(G) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(6)(H)(H) Biosimilar biological product(H) Biosimilar biological product
The term “biosimilar biological product” means a biological product approved under an abbreviated application for a license of a biological product that relies in part on data or information in an application for another biological product licensed under section 262 of this title.The term “biosimilar biological product” means a biological product approved under an abbreviated application for a license of a biological product that relies in part on data or information in an application for another biological product licensed under section 262 of this title.
(c)(6)(I)(I) Reference biological product(I) Reference biological product
The term “reference biological product” means the biological product licensed under such section 262 of this title that is referred to in the application described in subparagraph (H) of the biosimilar biological product.The term “reference biological product” means the biological product licensed under such section 262 of this title that is referred to in the application described in subparagraph (H) of the biosimilar biological product.
(c)(6)(J)(J) [inserted: Skin substitute products.—]
(c)(6)(J)(i)(i) [inserted: In general.—]
[inserted: The term “skin substitute product”—]
(c)(6)(J)(i)(I)(I) [inserted: ]
[inserted: means a cellular, biological or synthetic material or tissue applied to a wound and intended to remain within the wound bed, including a product approved, cleared, or authorized to section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(k), 260c(f)(2), 360e) or section 361 of the Public Health Service Act (42 U.S.C. 264), and their implementing regulations; and]
(c)(6)(J)(i)(II)(II) [inserted: ]
[inserted: does not include—]
(c)(6)(J)(i)(II)(aa)(aa) [inserted: ]
[inserted: any product that is intended to temporarily protect or cover the wound bed and be removed before complete resorption, such as a dressing;]
(c)(6)(J)(i)(II)(bb)(bb) [inserted: ]
[inserted: any liquid, gel, powder, or other similarly constituted item; or]
(c)(6)(J)(i)(II)(cc)(cc) [inserted: ]
[inserted: any product that would otherwise meet the requirements of subclause (I), but is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351(a) of the Public Health Service Act (42 U.S.C. 262(a)).]
(c)(6)(J)(ii)(ii) [inserted: Consolidated billing and payment code.—]
[inserted: Not later than January 1, 2026, the Secretary shall establish a new billing and payment code for all skin substitute products.]
(c)(6)(J)(iii)(iii) [inserted: Special rules.—]
[inserted: Beginning on January 1, 2026, the following rules shall apply:]
(c)(6)(J)(iii)(I)(I) [inserted: ]
[inserted: Each skin substitute product shall be subject to the same criteria when determining whether such skin substitute product is reasonable and necessary for the diagnosis or treatment of illness or injury under section 1862(a)(1)(A), unless determined by the Secretary that such product is unsafe based on evidence of contamination, serious infectious disease, or serious adverse reactions caused by such product.]
(c)(6)(J)(iii)(II)(II) [inserted: ]
[inserted: The Secretary may not determine that a skin substitute product is not considered reasonable and necessary for the diagnosis or treatment of illness or injury under section 1862(a)(1)(A) based solely on analysis of any clinical evidence relating to such product.]
(c)(6)(J)(iii)(III)(III) [inserted: ]
[inserted: A manufacturer of a skin substitute product shall not be required to report the average sales price for such product under section 1927(b)(3)(A)(iii) or subsection (f)(2).]
(d)(d) Monitoring of market prices(d) Monitoring of market prices
(d)(1)(1) In general(1) In general
The Inspector General of the Department of Health and Human Services shall conduct studies, which may include surveys, to determine the widely available market prices of drugs and biologicals to which this section applies, as the Inspector General, in consultation with the Secretary, determines to be appropriate.The Inspector General of the Department of Health and Human Services shall conduct studies, which may include surveys, to determine the widely available market prices of drugs and biologicals to which this section applies, as the Inspector General, in consultation with the Secretary, determines to be appropriate.

Rest of § 1395w–3a unchanged

Step through the changes